Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma
Compared with historic controls, re-irradiation plus pembrolizumab seemed to improve survival among bevacizumab-refractory patients but not among bevacizumab-naïve patients. CODEX revealed evidence of intratumoral infiltration of activated immune effector cells. A randomized, properly controlled trial of PD-1 blockade plus re-irradiation is warranted to further evaluate this regimen for bevacizumab-refractory patients, but alternative approaches are needed for bevacizumab-naïve patients.
Authors
- Maxime Meylan (ORCID: https://orcid.org/0000-0002-6175-1954)
- Julia Hayden (ORCID: https://orcid.org/0000-0002-8816-5672)
- Ye Tian (ORCID: https://orcid.org/0000-0002-9655-7123)
- Shyam Kumar Tanguturi (ORCID: https://orcid.org/0000-0001-6479-1946)
- Eric Wong (ORCID: https://orcid.org/0000-0001-7145-6038)
- Stephen Bagley (ORCID: https://orcid.org/0000-0002-7117-0539)
- Georges Ayoub (ORCID: https://orcid.org/0000-0002-1694-6779)
- Keith Lloyd Ligon (ORCID: https://orcid.org/0000-0002-7733-600X)
- Arati Desai (ORCID: https://orcid.org/0000-0002-4849-4703)
- Alona Muzikansky (ORCID: https://orcid.org/0000-0001-7585-8181)
- Lauren Hertan (ORCID: https://orcid.org/0000-0003-4558-8381)
- Lakshmi Nayak (ORCID: https://orcid.org/0000-0003-2725-8717)
- Patrick Yung Wen (ORCID: https://orcid.org/0000-0002-0774-7700)
- Robert A. Lustig (ORCID: https://orcid.org/0000-0003-0633-3802)
- Kai W. Wucherpfennig (ORCID: https://orcid.org/0000-0002-1829-302X)
- Tony J. C. Wang (ORCID: https://orcid.org/0000-0001-5809-3025)
- Graham L. Barlow (ORCID: https://orcid.org/0000-0001-9335-5414)
- David M. Meredith (ORCID: https://orcid.org/0000-0002-7054-8624)
- David A. Reardon (ORCID: https://orcid.org/0000-0001-6674-0157)
- Kun Huang (ORCID: https://orcid.org/0000-0002-9100-9638)
- Daphne Adele Haas-Kogan (ORCID: https://orcid.org/0000-0002-2378-4800)
- FABIO MASSAITI IWAMOTO (ORCID: https://orcid.org/0000-0003-1397-9927)
- Connor C. Bossi (ORCID: https://orcid.org/0000-0003-4922-2723)
- Christine McCluskey (ORCID: https://orcid.org/0000-0001-5610-8115)
- Shreya Nakhawa (ORCID: https://orcid.org/0009-0000-3860-6209)
- Julia Japo
- Paul Speliakos (ORCID: https://orcid.org/0009-0006-3482-5408)
Institutions
- Brigham and Women's Hospital (US)
- Beth Israel Deaconess Medical Center (US)
- Inserm (FR)
- Columbia University Irving Medical Center (US)
- Massachusetts General Hospital (US)
- Centre de Recherche des Cordeliers (FR)
- Center for Neuro-Oncology (US)
- Dana-Farber Cancer Institute (US)
- Dana-Farber Brigham Cancer Center (US)
- Columbia University (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-11-08
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-1629
- Citations
- 5
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.19
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Gilead Sciences
- Ben and Catherine Ivy Foundation
- Novocure
- Incyte
- Servier